

What is claimed is:

1. A method for determining whether a subject has a pediatric neoplasm, comprising assaying a diagnostic sample of the subject for Id2 expression, wherein detection of Id2 expression is diagnostic of a pediatric neoplasm.
2. The method of Claim 1, wherein the pediatric neoplasm is a neuroblastoma.
3. The method of Claim 1, wherein the diagnostic sample is assayed using an agent reactive with Id2.
4. The method of Claim 3, wherein the agent is labeled with a detectable marker.
5. The method of Claim 3, wherein the agent is an antibody.
6. The method of Claim 5, wherein the antibody is labeled with a detectable marker.
7. The method of Claim 1, wherein the diagnostic sample is assayed using at least one nucleic acid probe which hybridizes to nucleic acid encoding Id2.
8. The method of Claim 7, wherein the nucleic acid probe is DNA or RNA.
9. The method of Claim 8, wherein the nucleic acid probe is labeled with a detectable marker.

10. A method for assessing the efficacy of therapy to treat a pediatric neoplasm in a subject who has undergone or is undergoing treatment for a pediatric neoplasm, comprising assaying a diagnostic sample of the subject for Id2 expression, wherein detection of Id2 expression in the diagnostic sample is indicative of a need to continue therapy to treat the pediatric neoplasm, and an absence of Id2 expression in the diagnostic sample is indicative of successful therapy.

11. The method of Claim 10, wherein the pediatric neoplasm is a neuroblastoma.

12. The method of Claim 10, wherein the diagnostic sample is assayed using an agent reactive with Id2.

13. The method of Claim 12, wherein the agent is labeled with a detectable marker.

14. The method of Claim 12, wherein the agent is an antibody.

15. The method of Claim 14, wherein the antibody is labeled with a detectable marker.

16. The method of Claim 10, wherein the diagnostic sample is assayed using at least one nucleic acid probe which hybridizes to nucleic acid encoding Id2.

17. The method of Claim 16, wherein the nucleic acid probe is DNA or RNA.

18. The method of Claim 17, wherein the nucleic acid probe is labeled with a detectable marker.

19. A method for assessing the prognosis of a subject who has a pediatric neoplasm, comprising assaying a diagnostic sample of the subject for Id2 expression, wherein the subject's prognosis improves with a decrease in Id2 expression in the diagnostic sample, the subject's prognosis worsens with an increase in Id2 expression in the diagnostic sample, the subject's prognosis is favorable at low levels of Id2 expression in the diagnostic sample, and the subject's prognosis is unfavorable at high levels of Id2 expression in the diagnostic sample.

20. The method of Claim 19, wherein the pediatric neoplasm is a neuroblastoma.

21. A method for treating a pediatric neoplasm in a subject in need of treatment thereof, comprising inhibiting Id2.

22. The method of Claim 21, wherein the pediatric neoplasm is a neuroblastoma.

23. The method of Claim 21, wherein Id2 is inhibited by administering to the subject an amount of an Id2 inhibitor effective to treat the pediatric neoplasm in the subject.

24. The method of Claim 23, wherein the Id2 inhibitor is an agent reactive with Id2.

25. The method of Claim 23, wherein the Id2 inhibitor is an oligonucleotide antisense to Id2.